IV Brazilian guidelines for autoantibodies on HEp-2 cells

Paulo Luiz Carvalho Francescantonio1, Wilson de Melo Cruvinel1, Alessandra Dellavance2

  • 1Pontifícia Universidade Católica de Goiás, Goiânia, GO, Brasil.

Insights

The Fourth Brazilian Consensus for Autoantibodies Screening in HEp-2 Cells (ANA) updated guidelines for indirect immunofluorescence assays. New patterns were added, emphasizing quality control and standardization for accurate autoantibody detection.

Area of Science:

  • Immunology
  • Cell Biology
  • Medical Diagnostics

Background:

  • Indirect immunofluorescence (IIF) on HEp-2 cells is a primary method for detecting antinuclear antibodies (ANA).
  • Standardization and interpretation of ANA patterns are crucial for accurate autoimmune disease diagnosis.
  • Previous consensus meetings have guided ANA testing in Brazil, but evolving techniques necessitate updates.

Purpose of the Study:

  • To establish updated recommendations for ANA screening using HEp-2 cells in Brazil.
  • To discuss strategies for technique, standardization, interpretation, and quality control of IIF assays.
  • To address challenges in ANA pattern recognition and commercial kit variability.

Main Methods:

  • Convened twenty-three experts in ANA testing from Brazilian academic and private laboratories.
  • Facilitated discussions and consensus-building on recommendations for the fourth edition of the Brazilian ANA Consensus.
  • Reviewed and agreed upon updates to the ANA testing algorithm and quality control measures.

Main Results:

  • Incorporated three new patterns into the ANA algorithm: cytoplasmic Rods and Rings, nuclear Quasi-homogeneous, and CENP-F.
  • Highlighted the complex mixed pattern associated with anti-DNA topoisomerase I (Scl-70) antibodies.
  • Stressed the importance of continuous quality control, standardized screening dilutions, and conjugate titration.

Conclusions:

  • The 4th ANA Consensus provides updated guidelines for ANA screening in Brazil.
  • Emphasis on novel patterns, detailed description of complex patterns (e.g., Scl-70), and robust quality control is essential.
  • Acknowledged commercial kit heterogeneity and recommended solid-phase methods for autoantibody confirmation.
Abstract

Related Concept Videos